title: The potential impact of new National Osteoporosis Foundation guidance on treatment patterns.
abstract: This analysis of National Health and Nutrition Examination Survey III data describes the prevalence of risk factors for osteoporosis and the proportions of men and postmenopausal women age 50 years and older who are candidates for treatment to lower fracture risk, according to the new FRAX-based National Osteoporosis Foundation Clinician's Guide.
  
  
  BACKGROUND
  Little information is available on prevalence of osteoporosis risk factors or proportions of US men and women who are potential candidates for treatment.
  
  
  METHODS
  The prevalence of risk factors used in the new National Osteoporosis Foundation (NOF) FRAX-based Guide to the Prevention and Treatment of Osteoporosis was estimated using data from the third National Health and Nutrition Examination Survey (NHANES III). Risk factors not measured in NHANES III were simulated using World Health Organization cohorts. The proportion of US men and postmenopausal women age 50+ years who are treatment candidates by the new NOF Guide were calculated; for non-Hispanic white (NHW) women, the proportion eligible by the new NOF Guide was compared with that based on an earlier NOF Guide.
  
  
  RESULTS
  Twenty percent of men and 37% of women were potential candidates for treatment to prevent fractures by the new NOF Guide. Among NHW women, 53% were potential candidates by the previous NOF Guide compared with 41% by the new guide.
  
  
  CONCLUSIONS
  One fifth of men and 37% of postmenopausal women are eligible for osteoporosis treatment consideration by the new NOF Guide. However, fewer NHW women are eligible by the new guide than by the previous NOF Guide.
authors.affiliation: Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA 02111, USA. bess.dawson-hughes@tufts.edu
authors.forename: B
authors.initials: B
authors.lastname: Dawson-Hughes
authors.forename: A C
authors.initials: AC
authors.lastname: Looker
authors.forename: A N A
authors.initials: AN
authors.lastname: Tosteson
authors.forename: H
authors.initials: H
authors.lastname: Johansson
authors.forename: J A
authors.initials: JA
authors.lastname: Kanis
authors.forename: L J
authors.initials: LJ
authors.lastname: Melton
mesh_terms: D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D000886:Anthropometry / Q000379:methods; D001172:Arthritis, Rheumatoid / Q000150:complications; D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D005260:Female; D005272:Femur Neck / Q000503:physiopathology; D006801:Humans; D008159:Lumbar Vertebrae / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology / Q000503:physiopathology; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology; D058866:Osteoporotic Fractures / Q000453:epidemiology / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D018579:Patient Selection; D017410:Practice Guidelines as Topic; D018570:Risk Assessment / Q000379:methods; D012307:Risk Factors; D017678:Sex Distribution; D012907:Smoking / Q000009:adverse effects
chemical_list: D050071:Bone Density Conservation Agents
references.citation: Am J Med. 2003 Aug 15;115(3):209-16
references.pmid: 12947959
references.citation: J Womens Health (Larchmt). 2006 Mar;15(2):155-61
references.pmid: 16536679
references.citation: J Rheumatol. 2008 Feb;35(2):319-26
references.pmid: 18061977
references.citation: JAMA. 2004 Jun 16;291(23):2847-50
references.pmid: 15199035
references.citation: Exp Gerontol. 1994 May-Aug;29(3-4):479-93
references.pmid: 7925766
references.citation: Osteoporos Int. 2009 May;20(5):687-94
references.pmid: 18797813
references.citation: Osteoporos Int. 2007 May;18(5):585-91
references.pmid: 17146592
references.citation: J Bone Miner Res. 2009 Apr;24(4):675-80
references.pmid: 19049330
references.citation: Arthritis Rheum. 2008 Jan;58(1):15-25
references.pmid: 18163481
references.citation: Arch Intern Med. 2005 Nov 14;165(20):2414-9
references.pmid: 16287772
references.citation: Respir Care. 2001 Nov;46(11):1201-14
references.pmid: 11679142
references.citation: Am J Clin Nutr. 2008 Dec;88(6):1519-27
references.pmid: 19064511
references.citation: Arch Intern Med. 2002 Oct 28;162(19):2217-22
references.pmid: 12390065
references.citation: JAMA. 2002 Feb 27;287(8):1003-10
references.pmid: 11866648
references.citation: Osteoporos Int. 2008 Nov;19(11):1527-40
references.pmid: 18373049
references.citation: Arthritis Rheum. 2003 Apr;48(4):917-26
references.pmid: 12687533
references.citation: Osteoporos Int. 2008 Apr;19(4):437-47
references.pmid: 18292976
references.citation: Osteoporos Int. 2007 Aug;18(8):1033-46
references.pmid: 17323110
references.citation: Health Aff (Millwood). 2007 May-Jun;26(3):716-25
references.pmid: 17485749
references.citation: Osteoporos Int. 1991 Feb;1(2):95-102
references.pmid: 1790399
references.citation: J Bone Miner Res. 2007 Mar;22(3):465-75
references.pmid: 17144789
references.citation: Osteoporos Int. 2002 Aug;13(8):657-62
references.pmid: 12181625
references.citation: J Bone Miner Res. 1994 Jun;9(6):951-60
references.pmid: 8079669
references.citation: J Bone Miner Res. 2008 Jul;23(7):1061-7
references.pmid: 18302495
references.citation: Osteoporos Int. 1998;8(5):468-89
references.pmid: 9850356